NOVARTIS AG |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 88.82 CHF | +0.65% |
|
-0.69% | +5.03% |
| 10:44am | NOVARTIS AG : UBS maintains a Buy rating | ZD |
| 05-02 | Health Care Flat Amid Mixed Earnings -- Health Care Roundup | DJ |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 48.96B 44.34B 66.95B | Sales 2025 * | 50.79B 46B 69.45B | Capitalization | 198B 180B 271B |
|---|---|---|---|---|---|
| Net income 2024 * | 10.29B 9.32B 14.07B | Net income 2025 * | 12.05B 10.91B 16.47B | EV / Sales 2024 * | 4.32 x |
| Net Debt 2024 * | 12.88B 11.66B 17.61B | Net Debt 2025 * | 11.28B 10.21B 15.42B | EV / Sales 2025 * | 4.13 x |
| P/E ratio 2024 * |
19.3
x | P/E ratio 2025 * |
16.5
x | Employees | 76,057 |
| Yield 2024 * |
3.71% | Yield 2025 * |
3.85% | Free-Float | 85.22% |
More Fundamentals
* Assessed data
More news
Latest transcript on Novartis AG
More recommendations
More press releases
More news
| 1 day | +0.65% | ||
| 1 week | -0.69% | ||
| Current month | -0.89% | ||
| 1 month | +2.20% | ||
| 3 months | -1.70% | ||
| 6 months | +5.50% | ||
| Current year | +5.03% |
1 week
88.25
89.81
1 month
84.1592.23
Current year
84.1592.44
1 year
83.3494.85
3 years
73.1494.85
5 years
73.1494.85
10 years
68.07103.03
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 48 | 04-12-31 | |
| Director of Finance/CFO | 59 | 02-12-31 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 22-05-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 12-12-31 |
Simon Moroney
BRD | Director/Board Member | 65 | 20-02-27 |
| Chairman | 68 | 12-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-06 | 88.82 | +0.65% | 68 632 |
| 24-05-03 | 88.25 | -0.93% | 250,000 |
| 24-05-02 | 89.08 | -0.60% | 250,000 |
| 24-04-30 | 89.62 | +0.20% | 250,000 |
| 24-04-29 | 89.44 | -0.42% | 250,000 |
Delayed Quote Swiss Exchange, May 06, 2024 at 05:53 am
More quotes
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
97.24
USD
Average target price
108.4
USD
Spread / Average Target
+11.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.08% | 662B | |
| +22.60% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 289B | |
| +13.68% | 234B | |
| -10.80% | 194B | |
| +8.08% | 167B | |
| -3.40% | 157B |
- Stock Market
- Equities
- NOVN Stock
- NOVNEE Stock